EuroPCR 2024: Late-Breaking Science Video Collection

Up Next

EuroPCR 2024: Late-Breaking Science Video Collection

Average (ratings)
No ratings
Your rating
About the episode

EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.

The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary intervention (PCI). Within this patient group, 40% are expected to be affected by multivessel disease, and 30% by acute coronary syndrome.

Interview Questions:

  1. What is the reasoning behind this study?
  2. Could you tell us a bit more about the Abluminus DES+ SES?
  3. What was the patient population and study design?
  4. What are your key findings?
  5. What are your take-home messages for clinicans?
  6. What are the next steps?

Recorded onsite at EuroPCR Conference, Paris, 2024.

Editor: Jordan Rance
Video Specialists: Dan Brent, 
Interviewer: Liam O'Neill

Overview

Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.

More from this programme

Part 1

Expert Interviews

6 sessions
Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Watch now
Influence of Pathophysiological Patterns of CAD on PCI Watch now
Ancillary SMART Trial Analyses Watch now
Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY Watch now
TAVR Vs SAVR in Younger Low-Risk Patients with Severe Aortic Valve Stenosis: NOTION-2 Watch now
1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II Watch now

Part 2

View from the Thoraxcenter

2 sessions
View from the Thoraxcenter: What's Hot at EuroPCR 24? Watch now
View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1 Watch now

Part 3

Highlights Reviews

2 sessions
5 Trials That Will Change My Practice With Dr Mirvat Alasnag Watch now
4 Trials That Will Change My Practice with Dr Bernardo Cortese Watch now

Faculty Biographies

Roxana Mehran

Roxana Mehran

Professor of Medicine, Cardiology and Professor of Population Health Science and Policy

Roxana Mehran is an internationally recognised interventional cardiologist and clinical researcher based in New York, United States. She has spent much of her professional career at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, where she has become a leading figure in cardiovascular clinical trials, interventional cardiology, and outcomes research. Her work is widely noted for its focus on improving patient outcomes, advancing evidence-based care, and promoting sex-specific research in cardiovascular medicine.

 

Academic History

Professor Mehran pursued her medical education and postgraduate training in internal medicine and cardiology, followed by subspecialty training in interventional cardiology. Her academic career has been closely aligned with Mount Sinai, where she has advanced through senior academic ranks.

She currently holds appointments as Professor of Medicine (Cardiology) and Professor of Population Health Science…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.